Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...
Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...
By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...
In early March 2026, Genevant Sciences and Arbutus Biopharma said they had reached a US$2.25 billion global settlement with ...
Moderna agreed to pay up to $2.25 billion to settle a long‑running COVID vaccine patent dispute. The deal ends years of legal challenges.
2d
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang
Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the ...
Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ...
The Cambridge-based drug maker said the deal settles "all worldwide" litigation related to certain drugs and it won't have to pay royalties to other companies.
March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences, and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the ...
Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines.
A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.
The Food and Drug Administration’s controversial vaccine chief, Dr. Vinay Prasad, is once again leaving the agency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results